Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2987123 | The Journal of Thoracic and Cardiovascular Surgery | 2006 | 9 Pages |
Abstract
Gossypol profoundly sensitizes thoracic cancer cells to the cytotoxic effect of Apo2L/TRAIL via activation of the mitochondria-dependent death signaling pathway. This study provides evidence for the profound anticancer activity of this drug combination and should be further evaluated as a novel targeted molecular therapeutic for thoracic cancers.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Wen-Shuz PhD, Aris Baras, Alex Chua, Duc M. Nguyen, Shailen S. BS, David S. MD, FACS, Dao M. MD, MS, FRCSC, FACS,